Exact Sciences Cor (EXAS) Stock Price, Quote & News

Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Te...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 608 284 5700

Website: www.exactsciences.com

Address:

5505 Endeavor Lane, Madison, United States

GordoHLYK13 May. 20 at 12:13 PM

$NEO Back in 2018 I held 1k shares of NeoGenomics at a $13 average and watched it run to $60. Fast forward to 2026… now I’m holding 4k shares at $8.56 and the setup honestly looks even stronger. NEO today isn’t the same company from 2018 — bigger revenue, deeper oncology relationships, more advanced molecular testing, AI-driven diagnostics, and expanding precision medicine exposure. While everyone chases hype, NEO is quietly building a real cancer diagnostics powerhouse. The business is making substantially more money than it was during the last major run, yet the stock trades at a fraction of those levels. If execution keeps improving and margins expand, this could easily feel like NeoGenomics 4.0. 🚀 $NEO making way more money than the 2018 run to $60… yet trading near $8. Different beast now — stronger tech, bigger oncology footprint, AI diagnostics growth, and huge upside if sentiment flips. NeoGenomics 4.0 loading. 🔥 $TEM $NTRA $GH $EXAS

1 · Reply

DoctrBenway May. 12 at 1:40 PM

$GERN Uptake takes time. Stay long and the numbers continually become more compelling as hematologists (prone to inertia until something is proven compellingly better) change their practice in MDS/MF. Analogy: I knew Cologuard would have uptake and bought tons of $EXAS in the $4 range, I knew low risk patients would eschew a prep and procedure once the diagnostic follow-up was covered.

0 · Reply

Enjoy_Life_Bro May. 8 at 7:14 PM

$ABT $EXAS and poor leadership killed this. Not recovering any time soon

0 · Reply

malphius May. 8 at 6:17 PM

$EXAS Did you know there is an overlap with $HUMA and the board of directors? Did you know that 1 share of EXAS will buy 100 shares of $HUMA right before their June 11 V012 Phase 3 catalyst to unlock the Dialysis market?

1 · Reply

Stockprofiler May. 6 at 4:57 PM

$VNRX New Article. VolitionRx is stacking catalysts heading into Q4 2026 — finger-prick sepsis detection, French reimbursement, a $5M vet milestone, and licensing talks with 10 major diagnostics players. Revenue up 40%. Not financial advice. DYOR. https://allcapresearch.com/f/volitionrx-vnrx-stacking-catalysts-into-q4-2026 $EXAS $ILMN $PACB $NTRA

1 · Reply

Enjoy_Life_Bro May. 5 at 1:56 PM

$ABT Grossly overpaid for $EXAS . Now employees and shareholders suffer. Do something leadership!!!!

1 · Reply

FundaTech May. 1 at 6:44 PM

$ABT The acquisition of $EXAS was a very good strategic deal that refreshes its diagnostics story and bets on secular tailwinds in oncology/prevention. Near-term pain (dilution, stock reaction) is typical for large accretive-over-time acquisitions, but the +3B sales addition and margin/synergy upside support long-term value if integration succeeds. Many analysts see it enhancing Abbott’s growth profile.

0 · Reply

GordoHLYK13 Apr. 29 at 11:17 AM

$NEO $EXAS $GH $NTRA $NEO move is no pump n dump — this is what a real fundamental breakout looks like. 🚀 NEO ripping premarket is a direct reaction to legit catalysts, not hype: 🔥 Q1 Earnings Beat • Revenue came in at $187M, beating Wall Street • Clinical revenue up 14% YoY • High-margin NGS revenue exploded 26% • Management RAISED 2026 guidance to $797M–$803M 🔥 Analyst Upgrades Rolling In • Leerink upgraded to Outperform and doubled PT from $12 to $25 • Benchmark also upgraded to Buy 🔥 MolDX Approval PanTracer liquid biopsy getting reimbursement support is a game changer — opens the door for recurring revenue and lowers risk big time. 💰 Heavy volume + better numbers + raised guidance + analysts chasing = smart money stepping in. This isn’t a pump… this is institutions repricing NEO higher. 📈

0 · Reply

StocktwitsNews Apr. 17 at 5:19 AM

LCID, ABT, ASBP Stocks Hit 52-Week Lows Today: What’s Driving The Selloff? $LCID $ABT $ASBP $EXAS https://stocktwits.com/news/equity/markets/why-lcid-abt-asbp-stocks-hit-52-week-lows-today/cZJUhKPRIxB

0 · Reply

WycklyTrader Apr. 2 at 4:17 AM

KALV / PHVS potential big pharma acquisitions for hereditary angioedema (HAE) treatments. $APLS $DAWN $FOLD $EXAS $CNTA . BEP energy play.

0 · Reply

Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

Mar 4, 2026, 9:00 AM EST - 2 months ago

Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year

Mar 3, 2026, 10:00 AM EST - 2 months ago

Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration

PRVA

Feb 20, 2026, 4:05 PM EST - 3 months ago

Exact Sciences Stockholders Approve Acquisition by Abbott

ABT

Feb 13, 2026, 4:05 PM EST - 3 months ago

Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results

Feb 6, 2026, 4:03 PM EST - 3 months ago

Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences' '746 Patent

Feb 3, 2026, 2:32 PM EST - 3 months ago

Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests

Feb 3, 2026, 9:03 AM EST - 3 months ago

Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide

Dec 30, 2025, 9:31 AM EST - 5 months ago

Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims

Dec 11, 2025, 5:30 PM EST - 5 months ago

Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS

Nov 24, 2025, 4:35 PM EST - 6 months ago

Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium

Nov 21, 2025, 8:30 PM EST - 6 months ago

Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS

ABT

Nov 20, 2025, 6:45 PM EST - 6 months ago

Why the Stock Price of This Cancer Screening Company Soared 17% Thursday

Nov 20, 2025, 3:13 PM EST - 6 months ago

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Exact Sciences Corporation (Nasdaq – EXAS)

Nov 20, 2025, 1:29 PM EST - 6 months ago

Is it too late to buy Exact Sciences stock after Abbott's $21B deal?

Nov 20, 2025, 1:26 PM EST - 6 months ago

Top Stock Movers Now: Walmart, Nvidia, Exact Sciences, Bath and Body Works, and More

BBWI NVDA WMT

Nov 20, 2025, 8:43 AM EST - 6 months ago

Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test

ABT

Nov 20, 2025, 7:46 AM EST - 6 months ago

Abbott to Acquire Exact Sciences for $21 Billion

ABT

Nov 20, 2025, 7:46 AM EST - 6 months ago

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.

ABT

Nov 20, 2025, 7:36 AM EST - 6 months ago

Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences

ABT

Nov 20, 2025, 7:30 AM EST - 6 months ago

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

ABT

Nov 19, 2025, 4:27 PM EST - 6 months ago

Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories

ABT

Nov 19, 2025, 1:50 PM EST - 6 months ago

Abbott is weighing takeover of Exact Sciences, Bloomberg News reports

ABT

Nov 10, 2025, 7:00 AM EST - 7 months ago

Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome's Blood-Based Colorectal Cancer Screening Tests

Nov 7, 2025, 8:00 AM EST - 7 months ago

Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test

Nov 4, 2025, 7:00 AM EST - 7 months ago

Exact Sciences to Participate in November Investor Conference

Nov 3, 2025, 4:05 PM EST - 7 months ago

Exact Sciences Announces Third Quarter 2025 Results

Oct 27, 2025, 7:00 AM EDT - 7 months ago

Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps

Oct 8, 2025, 7:00 AM EDT - 8 months ago

Exact Sciences Schedules Third Quarter 2025 Earnings Call

Oct 7, 2025, 6:59 AM EDT - 8 months ago

New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies

Sep 22, 2025, 7:00 AM EDT - 8 months ago

Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test

Sep 17, 2025, 8:30 AM EDT - 8 months ago

Healthmine and Exact Sciences Partner to Combine At-Home CRC Screening with Health Plan Incentives to Boost Preventive Care

Sep 15, 2025, 3:30 PM EDT - 9 months ago

Exact Sciences CEO on Launch of Multi-Cancer Blood Test

Sep 10, 2025, 6:30 AM EDT - 9 months ago

Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test

Aug 22, 2025, 8:05 AM EDT - 9 months ago

Legal Win for Geneoscopy as Exact Sciences Withdraws Preliminary Injunction Against ColoSense®

Aug 19, 2025, 6:00 AM EDT - 10 months ago

Exact Sciences to Participate in September Investor Conferences

Aug 6, 2025, 4:05 PM EDT - 10 months ago

Exact Sciences Announces Second Quarter 2025 Results

Aug 6, 2025, 4:05 PM EDT - 10 months ago

Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests

Jul 31, 2025, 7:00 AM EDT - 10 months ago

Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test

Jul 14, 2025, 6:00 AM EDT - 11 months ago

Exact Sciences Schedules Second Quarter 2025 Earnings Call

Jul 10, 2025, 11:19 AM EDT - 11 months ago

Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences' '781 Patent

Jul 9, 2025, 6:00 AM EDT - 11 months ago

Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer

May 28, 2025, 6:05 AM EDT - 1 year ago

Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap

May 27, 2025, 4:05 PM EDT - 1 year ago

Exact Sciences to Participate in June Investor Conference

May 22, 2025, 5:05 PM EDT - 1 year ago

Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

May 12, 2025, 10:00 AM EDT - 1 year ago

Exact Sciences Earns 2025 Great Place To Work® Certification™

GordoHLYK13 May. 20 at 12:13 PM

1 · Reply

DoctrBenway May. 12 at 1:40 PM

0 · Reply

Enjoy_Life_Bro May. 8 at 7:14 PM

$ABT $EXAS and poor leadership killed this. Not recovering any time soon

0 · Reply

malphius May. 8 at 6:17 PM

1 · Reply

Stockprofiler May. 6 at 4:57 PM

1 · Reply

Enjoy_Life_Bro May. 5 at 1:56 PM

$ABT Grossly overpaid for $EXAS . Now employees and shareholders suffer. Do something leadership!!!!

1 · Reply

FundaTech May. 1 at 6:44 PM

0 · Reply

GordoHLYK13 Apr. 29 at 11:17 AM

0 · Reply

StocktwitsNews Apr. 17 at 5:19 AM

0 · Reply

WycklyTrader Apr. 2 at 4:17 AM

KALV / PHVS potential big pharma acquisitions for hereditary angioedema (HAE) treatments. $APLS $DAWN $FOLD $EXAS $CNTA . BEP energy play.

0 · Reply

CromieAds Apr. 1 at 1:46 PM

$CAI $EXAS $GH $GRAL

0 · Reply

CromieAds Mar. 31 at 11:44 PM

$CAI should run up nicely tomorrow. This is big news!… https://www.prnewswire.com/news-releases/caris-life-sciences-finalizes-achieve-1-study-results-reinforcing-the-superior-sensitivity-and-specificity-of-caris-detect-302730659.html $EXAS $GH $GRAL

1 · Reply

thingkfast Mar. 27 at 1:33 PM

$EXAS well I’m officially taking EXAS off my watchlist, what a ride it has been. Our flagship products are now in the hands of Abbott with worldwide reach and exposure!! It was great talking to everyone. Remember Freenome is going public under FRNM in the first half of this year!! Good luck to all

0 · Reply

julianjakobi Mar. 25 at 4:34 PM

Big congrats to everyone in $EXAS — insane run. A lot of us saw ~2000% gains, which honestly doesn’t happen often. I’ve personally rotated almost $ 1/2 Million of that into $BLGO. Different stage, but similar kind of setup in my opinion. Their Clyra Medical subsidiary is working on what could become a real game-changer in wound care with this copper-iodine tech. They’ve already locked in a deal with one of the top 4 medical companies, and from what I understand, products should hit the market this year once packaging clears. Manufacturing is ready for at least 2M units annually, so this isn’t some early concept anymore. The first product - ViaClyr - is just starting to roll out, and the bigger surgical push is expected later this year. Feels like one of those situations where the market hasn’t caught up yet. Definitely worth digging into if you’re looking for the next move post-EXAS. $EXAS $BLGO Check out what a woundcare specialist had to say in the photos attached.

3 · Reply

Easternbikes5 Mar. 25 at 1:23 PM

$EXAS guess my 4/17 calls for 105 are done. Originally seen the merger close in q2, $250 loss.

0 · Reply

FoolsInLove Mar. 25 at 3:26 AM

$EXAS im still waiting for the competitive bid from Pfizer…

0 · Reply

Gilgamesh Mar. 24 at 5:38 PM

$EXAS @Serafina1991 If you sella lot of $EXAS at a loss you can’t buy back within 30 days or you can’t take the tax loss. Buying a different biotech stock is not a problem-you can take the loss. Me lawyer.

0 · Reply

katico Mar. 24 at 2:55 PM

$EXAS wash sales would be triggered by purchases of what the IRS considers **like-kind** investments. This means if you are selling EXAS (or any share lots within your EXAS overall investment) at a loss, and you want to avoid a wash sale, you should not purchase another biotech stock for 31 days after the EXAS sale. The same would apply to any biotech purchases made 30 days prior to the EXAS sale. Hope this helps!

1 · Reply

30DeltaSpy Mar. 23 at 7:04 PM

$ABT + $EXAS Abbott closes $21B Exact Sciences deal https://www.chicagobusiness.com/health-care/ccb-abbott-exact-sciences-deal-closes/?utm_content=article8-headline&utm_source=afternoon-10&utm_medium=email&utm_campaign=20260323

0 · Reply

Serafina1991 Mar. 23 at 6:07 PM

$EXAS I would love to hear from other EXAS Investors who will have all of their shares purchased today/tomorrow. Overall, I will be seeing a nice long term gain but there are some lots (long loss) pockets that will be offsetting some of those profits. Will those losses within my overall profit from EXAS shares be considered a basis for a wash sale should I decide to purchase another Biotech's shares within 31 days? I know that Is how It usually works but I AM realizing an overall profit from the sale of all of my EXAS shares and It IS a buyout. Thanks for the anticipated discussion

2 · Reply

bearcreekzeke Mar. 23 at 4:58 PM

$EXAS Farewell and best of luck to you all my friends! One last Reddit post for you all. Please feel free to stop by and leave a comment - https://www.reddit.com/r/exactsciences/comments/1s1mbwy/exact_sciences_is_now_abbott/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button

0 · Reply

bearcreekzeke Mar. 23 at 4:55 PM

$EXAS For old time's sake: https://youtu.be/J2hI3-KvYZY?si=61TDSgT_-kAQQzV0

0 · Reply

Market Cap	20.03B
Revenue (ttm)	3.25B
Net Income (ttm)	-207.95M
EPS (ttm)	N/A
PE Ratio	2,598.00
Forward PE	61.35
Profit Margin	-6.40%
Debt to Equity Ratio	0.00

Volume	21,562,100
Avg Vol	2,640,294
Day's Range	N/A - N/A
Shares Out	190.89M
Stochastic %K	96%
Beta	1.41
Analysts	Sell
Price Target	$101.44